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Abstract
Background BRCA1/2 mutation prediction models
(BRCAPRO, Myriad II, Couch, Shattuck-Eidens, BO-
ADICEA) are well established in western cohorts to esti-
mate the probability of BRCA1/2 mutations. Results are
conﬂicting in Asian populations. Most studies did not
account for gender-speciﬁc prediction. We evaluated the
performance of these models in a Chinese cohort, including
males, before BRCA1/2 mutation testing.
Methods The ﬁve risk models were used to calculate the
probability of BRCA mutations in probands with breast and
ovarian cancers; 267 were non-BRCA mutation carriers
(247 females and 20 males) and 43 were BRCA mutation
carriers (38 females and 5 males).
Results Mean BRCA prediction scores for all models
were statistically better for carriers than noncarriers for
females but not for males. BRCAPRO overestimated the
numbers of female BRCA1/2 mutation carriers at thresh-
olds C20% but underestimated if \20%. BRCAPRO and
BOADICEA underestimated the number of male BRCA1/2
mutation carriers whilst Myriad II underestimated the
number of both male and female carriers. In females,
BRCAPRO showed similar discrimination, as measured by
the area under the receiver operator characteristic curve
(AUC) for BRCA1/2 combined mutation prediction to
BOADICEA, but performed better than BOADICEA in
BRCA1 mutation prediction (AUC 93% vs. 87%). BO-
ADICEA had the best discrimination for BRCA1/2 com-
bined mutation prediction (AUC 87%) in males.
Conclusions The variation in model performance under-
scores the need for research on larger Asian cohorts as
prediction models, and the possible need for customizing
these models for different ethnic groups and genders.
Introduction
The identiﬁcation of BRCA1 and BRCA2 mutations has
dramatically changed the landscape of breast cancer in the
past decade. Testing of these genes has become an
important part of clinical practice. Mutations in either of
these genes results in increased risk of breast and ovarian
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DOI 10.1007/s00268-011-1406-ycancer, accounting for 5% to 10% of breast cancers and
10% to 15% of ovarian cancers [1–4]. BRCA1 is mutated
more frequently in families with both breast and ovarian
cancer [5, 6] and more rarely in families with male breast
cancer where BRCA2 is predominant [7, 8].
Genetic testing, however, is expensive and may be
associated with adverse psychological effects not only to
the patient but also family members [9, 10]. Family history
of breast cancer is not uncommon, but BRCA mutations are
relatively rare. Establishing an efﬁcient way to identify a
‘‘high-risk group’’ accurately for genetic testing is impor-
tant for patient care. However, the prevalence of germline
BRCA mutations in these ‘‘high-risk families’’ is estimated
at 13–19% [11, 12]. These low ﬁgures lead to the devel-
opment of models (such as BOADICEA [13], BRCAPRO
[14–16], Myriad [11], Couch (also known as PENN) [17],
Shattuck-Eidens [18], and Manchester [19]) that can assess
the pre-test probability of identifying a BRCA1 or BRCA2
mutation and enable efﬁcient targeting of genetic testing.
Although these models were built by using data from
Caucasian populations, they are being used in clinical
practice to assess the risk of BRCA1/2 mutation carriage in
patients of other ethnic backgrounds [20–22] and have had
variable accuracy for African Americans and Hispanics in
the United States in different studies [20–23]. Indeed, the
chance of carrying a genetic mutation varies between dif-
ferent races and is most common in Ashkenazi Jewish
cohorts [24]. For ethnic populations where limited genetic
studies have been undertaken, variants of unknown sig-
niﬁcance detected may be benign mutation changes but
some may in fact be characterized to be pathogenic when
analyzed further at an RNA level [25]. Hence, evaluation
of the performance of these models in different ethnic
groups has been performed so that individuals who are at
risk can be accurately identiﬁed and be offered intensive
surveillance and preventative measures.
Although still less-tested than in Caucasian populations,
increasing numbers of Asian cohorts are being clinically
tested both in Asia and in western countries, such as the
United States [26–30]. A few studies have evaluated these
models in a mixture of different Asian or Chinese cohorts
[31–33]. Most of these studies found an underprediction of
BRCA2 mutations with a comparable discriminative ability
as for Caucasians. Moreover, none of the studies separately
analyzed the accuracy of the use of these models in pre-
diction of mutation carriage for males [32, 34], and
therefore, there is still limited reporting of gender-speciﬁc
prediction.
The purpose of our study was to compare the four
commonly used BRCA1/2 mutation prediction models
(BOADICEA, BRCAPRO, Myriad II, Couch and Shattuck-
Eidens) to determine the likelihood of ﬁnding a BRCA1,
BRCA2, or combined BRCA1/2 gene mutation in patients
residing in Hong Kong, who are mainly Southern China
origin Chinese, and to determine if these models can per-
form accurately for males.
Materials and methods
Study population
Participants were recruitedthroughthe prospective database
at The Hong Kong Hereditary and High Risk Breast Cancer
Family Registry (www.asiabreastregistry.com), which was
established in March 2007. Protocols of the study were
approved by Institutional Review Board of the participating
research centers. The Registry collects data from high-risk
probandsand familiesreferred tothe Hong Kong Hereditary
and High-Risk Breast Cancer Programme for consideration
of genetic testing. Female breast and ovarian cancer patients
were accrued based on age of onset, family history sugges-
tive of hereditary predisposition, bilateral breast cancer
status, and male breast cancer patients and were recruited
from public and private hospitals and centers covering all
areas of Hong Kong. Additional details of accrual were
published in a previous study [29]. An epidemiological
questionnaire, pedigree information about breast, ovarian,
and/or other cancers of the ﬁrst-, second-, and third-degree
relatives of each proband was obtained. Unknown ages and
unknownyearatdeathwereassumedtobe25 yearsbetween
each generation [35].
The CancerGene software program (CaGene 4.3, The
University of Texas Southwestern Medical Center, Dallas,
TX) was used to calculate the probability of BRCA1,
BRCA2, and BRCA1/2 mutation carriage from BRCAP-
RO, Myriad II, and Couch and Shattuck-Eidens models.
BOADICEA risk model was calculated through https://
pluto.srl.cam.ac.uk/cgi-bin/bd1/v1/bd.cgi using the most
updated software available. Couch and Shattuck-Eidens
models were only calculated in female participants.
All calculations were performed for male and female
patients separately to evaluate how accurately BRCAPRO,
Myriad II, Couch and Shattuck-Eidens, and BOADICEA
models predicted risks for male and female independently.
Independent t tests were used to compare any difference in
mean score computed by the ﬁve carrier prediction algo-
rithms between patients with and without BRCA mutation.
Pearson v
2 goodness of ﬁt test was used to compare the
number of mutations predicted by these risk models with
the actual number of mutation detected.
The area under the receiver operating characteristic
(ROC) curve with 95% conﬁdence interval for each model
was used to determine discrimination. ROC was evaluated
to compare the ability of these models to distinguish
between patients with and without a mutation and to
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123measure the overall performance of each model. The closer
the area under the ROC curve (AUC) is to 1, the better the
overall performance of the model. A model with an AUC
value of 1 is one that is perfectly accurate, whereas an
AUC of 0.5 indicates no discriminating ability. The refer-
ence line distinguishes subjects who carry the BRCA
mutation versus those who do not by pure chance. The
resulting ROC curve would fall along this diagonal line,
which is referred to as the chance diagonal. The empirical
estimates of the sensitivity and speciﬁcity for positive
BRCA status were calculated at the conventional testing
thresholds of 10 and 20 for BRCAPRO, Myriad II, and
BOADICEA models.
Fisher’s exact test was used to test for signiﬁcance for
small sample sizes. All tests were two-sided, and p val-
ues\0.05 were considered statistically signiﬁcant differ-
ence. All statistical analyses were performed with the SPSS
for Windows Release 16.0 (SPSS Inc., Chicago, IL).
Results
A total of 310 probands (285 females and 25 males) were
recruited. All were of Chinese ancestry. Among them, 267
(86.1%) individuals (247 females and 20 males) were
noncarriers and 43 (13.9%) individuals (38 females and 5
males) were mutation carriers. Among 285 female pro-
bands, most were breast cancer patients (98%), and 247
(86.7%), 15 (5.3%), and 23 (8.1%) were noncarriers,
BRCA1, and BRCA2 carriers respectively. Among 25 male
probands, 20 (80%) and 5 (20%) were noncarriers and
carriers respectively. All male mutation carriers had
BRCA2 mutations. Table 1 shows the characteristics of the
study population.
Table 2 shows the mean and median predicted proba-
bilities of mutation carriage for BRCA mutation carriers
and noncarriers for female patients. We found that there
was signiﬁcant difference in mean predicted probability by
all models for female BRCA carriers versus noncarriers.
BRCA mutation carriers generally had higher mean scores
than noncarriers. Table 3 shows that for males, none of the
models showed any signiﬁcant difference in mean pre-
dicted probability between BRCA carriers and BRCA
noncarriers, although BRCA mutation carriers had higher
model scores overall.
Observed and expected numbers of mutation carriers by
predicted carrier probability using the models are shown in
Tables 4, 5, and 6. BRCAPRO predictions are seen in
Table 4. In females, 16 BRCA1 and 25 BRCA2 mutation
carriers were predicted and 15 and 23 were observed
respectively. For a total BRCA mutation prediction of 41
carriers when 38 were observed (p for goodness of
ﬁt = 0.91), this model performed the closest predicted
carrier probability. In males, three, four, and three carriers
were predicted using BRCAPRO, Myriad II, and BO-
ADICEA models respectively and ﬁve were observed.
As shown in Table 5, Myriad II predicted 32 female
BRCA mutation carriers compared with the 38 observed
(p = 0.444). For males, four were predicted and ﬁve were
observed (p = 1.000). This was the best predictive model
for males.
BOADICEA (Table 6) predicted 13 BRCA1 and 19
BRCA2(32intotal)mutationcarrierscomparedwith15and
23 observed (38 in total) respectively (p = 0.723). In male
probands, BOADICEA predicted three BRCA2 mutation
carriers compared with ﬁve observed (p = 0.702).
For female probands, BRCAPRO (Table 4) tended to
underestimate the number of BRCA1 and BRCA2 carriers
at carrier probabilities \20%, but overestimated those
C20%. Myriad II (Table 5) underestimated the number of
BRCA1/2 mutation carriers for all carrier probabilities.
BOADICEA (Table 6) underestimated the number of
BRCA1 and BRCA2 carriers for carrier probabilities
\40%, but overestimated those C40%. All models
underestimated the expected number of males.
For BRCA1/2 prediction in females (Fig. 1a), the AUC
was 0.79 using BRCAPRO, 0.72 using Myriad II, and 0.8
using BOADICEA. BRCAPRO had greatest AUC in
BRCA1 speciﬁc (0.93) prediction compared with other
models, and the same BRCA2 speciﬁc (0.73) prediction in
females as BOADICEA. Conversely, the AUC was 0.8
using BOADICEA for BRCA1/2 mutation prediction in
females and 0.87 in males (Fig. 1b); both were the highest
scores compared with other models. Overall, BOADICEA
had the highest discriminating power in females and males.
Figures 1c and d show ROC curves for different models,
comparing female BRCA1 carriers and noncarriers and
BRCA2 carriers and noncarriers respectively. Figure 1e
illustrates ROC curves for different models comparing
male BRCA2 carriers and noncarriers.
Performance of BRCAPRO, Myriad II, Couch and
Shattuck-Eidens, and BOADICEA models at conventional
thresholds of 10% and 20% is shown in Table 7.I n
females, the highest sensitivity at both 10% and 20% cut-
offs was achieved by BRCAPRO for BRCA1/2 mutations
combined (73.7 and 57.9), BRCA1 mutations (86.7 and
66.7), and BRCA2 mutations (43.5 and 34.8), but its
speciﬁcity was slightly lower than BOADICEA.
In males, BOADICEA had similar sensitivity compared
with BRCAPRO at both 10% and 20% cutoffs (60 and 40)
in BRCA1/2 combined and BRCA2 (60 and 40) but a
higher speciﬁcity for BRCA1/2 combined (80 and 100 vs.
750 and 95) and BRCA2 speciﬁcity (85 and 100 vs. 75 and
95). Myriad II generally had a lower sensitivity and spec-
iﬁcity at both 10% and 20% cutoffs except for a slightly
high speciﬁcity at 20% in BRCA1/2 combined in females
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123(92.3). Couch and Shattuck-Eidens model had inferior
sensitivities and speciﬁcities overall in our cohort.
Discussion
Hong Kong, being the southern part of China, is a unique
place to study hereditary breast cancers in Chinese with
[80% of the study population originating from southern
China [29, 36]. Moreover, the one-child policy in Mainland
China is not practiced in Hong Kong, enabling larger
family structures for analysis, which is relevant because
limited familial history has been reported to result in
underestimation of mutation carriers by various prediction
models [33, 37]. In 2008, more than 2,600 new breast
cancer cases were diagnosed (Hong Kong Cancer Registry)
and it ranked the third most common cancer after lung and
colorectal malignancies and the most common cancer in
Table 1 Personal and family history of the probands (N = 310)
BRCA
Negative Positive All
n Col % n Col % n Col %
Female (n = 285)
Personal history of breast cancer
No 3 1.2 2 5.3 5 1.8
Yes 244 98.8 36 94.7 280 98.2
Personal history of ovarian cancer
No 242 98.0 31 81.6 273 95.8
Yes 5 2.0 7 18.4 12 4.2
Personal history of breast and ovarian cancer
No 245 99.2 33 86.8 278 97.5
Yes 2 0.8 5 13.2 7 2.5
Family history of breast cancer
No 4 1.6 1 2.6 5 1.8
Yes 243 98.4 37 97.4 280 98.2
No. of family members with breast cancer (among those with family history with breast cancer)
\3 223 91.8 21 56.8 244 87.1
C3 20 8.2 16 43.2 36 12.9
Family history of ovarian cancer
No 221 89.5 25 65.8 246 86.3
Yes 26 10.5 13 34.2 39 13.7
Family history of breast and ovarian cancer
No 221 89.5 26 68.4 247 86.7
Yes 26 10.5 12 31.6 38 13.3
Male (n = 25)
Personal history of breast cancer
N o 00 0 000
Yes 20 100 5 100 25 100
Family history of breast cancer
N o 00 0 000
Yes 20 100 5 100 25 100
No. of family members with breast cancer (among those with family history with breast cancer)
\3 20 100 4 80 24 96
C30 0 1 2 0 1 4
Family history of ovarian cancer
No 20 100 5 100 25 100
Y e s 00 0 000
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123Table 2 Difference in scoring systems between BRCA-positive and BRCA-negative using two independent t statistics: females
Mean Median Range tp value 95% CI
Female (n = 285)
Age diagnosed with breast cancer (year)
Noncarriers 44 44 18–82 1.48 0.14 (-0.92, 6.51)
Carriers 41.5 39 26–68
All
a 44 43.5 18–82
Among carriers with breast cancer
BRCA1 38 36 26–68 -1.75 0.089
# (-12.35, 0.92)
BRCA2 44 41 28–63
Age diagnosed with ovarian cancer (year)
Noncarriers 34 31 19–50 -2.38 0.039*( -30.23, -0.97)
Carriers 50 49 38–64
All
b 43.5 47.5 19–64
Among carriers with ovarian cancer
BRCA1 50 48 38–64 – – –
BRCA2 49 49 49
BRCA 1
Couch
BRCA negative 10.55 7.7 0–77 -3.04 0.004*( -19.58, -3.95)
BRCA positive 22.32 11.7 0–92.4
All 12.12 7.7 0–92.4
Shattuck-Eidens
BRCA negative 7.11 4.2 0–74.8 -3.04 0.004*( -16.71, -3.36)
BRCA positive 17.14 8.05 1.2–85.9
All 8.44 4.6 0–85.9
BRCAPRO
BRCA negative 5.65 0.5 0–93.8 -4 <0.001*( -33.41, -10.96)
BRCA positive 27.84 9.7 0–98.8
All 8.61 0.8 0–98.8
BOADICEA
BRCA negative 4.37 1.17 0.03–90.07 -3.67 <0.001*( -25.07, -7.26)
BRCA positive 20.53 7.75 0.24–99.41
All 6.52 1.41 0.03–99.41
BRCA 2
BRCAPRO
BRCA negative 4.55 1.2 0–61.4 -3.12 0.003*( -18.32, -3.91)
BRCA positive 15.67 6.65 0–81.6
All 6.04 1.6 0–81.6
BOADICEA
BRCA negative 3.62 1.72 0.07–39.1 -3.38 0.002*( -11.71, -2.95)
BRCA positive 10.95 6.5 0.04–59.98
All 4.59 1.82 0.04–59.98
Any BRCA
Myriad II
BRCA negative 9.75 6.8 2.8–53.9 -3.66 0.001*( -16.58, -4.79)
BRCA positive 20.43 15.8 2.9–79
All 11.17 6.8 2.8–79
BRCAPRO
BRCA negative 10.19 2.5 0–99.2 -5.54 <0.001*( -45.4, -21.12)
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123Table 3 Difference in scoring systems between BRCA-positive and BRCA-negative using two independent t statistics: males
Mean Median Range tp value 95% CI
Male (n = 25)
Age diagnosed with breast cancer (year)
Noncarriers 62 64 33–83 0.8 0.431 (-8.3, 18.8)
Carriers (all BRCA2) 57 56 47–74
All 61 63 33–83
BRCA 1
BRCAPRO
BRCA negative 0.47 0 0–7.2 0.17 0.867 (-1.4, 1.64)
BRCA positive 0.34 0.3 0–0.8
All 0.44 0 0–7.2
BOADICEA
BRCA negative 0.43 0.36 0.01–1.01 -1.34 0.192 (-0.45, 0.09)
BRCA positive 0.61 0.64 0.41–0.8
All 0.47 0.41 0.01–1.01
BRCA 2
BRCAPRO
BRCA negative 7.58 5.75 0–30.6 -1.37 0.241 (-69.88, 23.47)
BRCA positive 30.78 14.1 7.8–96.6
All 12.22 7.8 0–96.6
BOADICEA
BRCA negative 6.74 7.22 0.03–15.77 -1.55 0.195 (-71.44, 20.05)
BRCA positive 32.43 15.5 8.61–95.84
All 11.87 8.05 0.03–95.84
Any BRCA
Myriad II
BRCA negative 12.75 12.8 2.8–21.8 -1.35 0.247 (-23.28, 7.94)
BRCA positive 20.42 12.8 12.8–41.9
All 14.28 12.8 2.8–41.9
BRCAPRO
BRCA negative 8.04 5.75 0–30.8 -1.36 0.245 (-69.99, 23.82)
BRCA positive 31.12 14.1 7.8–97.2
All 12.65 7.8 0–97.2
BOADICEA
BRCA negative 7.17 7.58 0.04–16.64 -1.56 0.193 (-71.67, 19.93)
Table 2 continued
Mean Median Range tp value 95% CI
BRCA positive 43.45 42.35 0–100
All 14.62 3.2 0–100
BOADICEA
BRCA negative 7.98 2.99 0.1–93.85 -4.34 <0.001*( -34.45, -12.53)
BRCA positive 31.48 14.79 1.07–99.84
All 11.12 3.4 0.1–99.84
a There were ﬁve probands with ovarian cancer only, the number of patients with breast cancer is 280 (285-5)
b There were 12 probands in total with ovarian cancer (hence 7 with breast and ovarian cancers): 5 (41.7%) of them were noncarriers, 6 (50%)
were BRCA1, and 1 (8.3%) was BRCA2
# p\0.1 (marginal signiﬁcance); * p\0.05
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123females. An improved understanding of hereditary breast
cancer and more accurate selection of patients for genetic
testing will have important implications for economic
health policies.
A previous study performed by our group found 12.8%
of clinically high-risk Chinese probands with breast and/or
ovarian cancers carried a deleterious BRCA mutation, of
which 60.7% were BRCA2 mutations [29]. This is a higher
percentage of BRCA2 mutations compared with that of
most Caucasian cohorts where studies have found that the
prevalence of BRCA1 mutations ranges from 6.9% to 8.3%
in European and American Caucasians compared with
BRCA2 mutation prevalence of 5.2% to 5.9% [38–40],
although consistent with other ﬁndings in Asian countries
and a study performed by our group in Asian Americans
[33, 41–43]. Mutations tend to be population-speciﬁc so
different ethnic cohorts are likely to have a different
spectrum of mutations and also different founder mutations
[20, 44, 45]. In fact in a previous study, we reported a
BRCA2 founder mutation in our cohort, which has
accounted for the larger proportions of BRCA2 mutation
carriers in our locality [36]. All of these differences are
likely to result in inaccuracies in the use of existing pre-
diction models, which have been designed based on Cau-
casian cohorts.
Asians comprise 57% of the world’s population and
Chinese represent the largest group in the Asia continent
[46], many of whom reside in western countries, such as
the United States, where 4.2% of the population are Asian
Americans. Therefore, Asian-speciﬁc studies and the
accuracy of risk prediction models for use in this group
would be of clinical relevance worldwide.
Our study indicated that BOADICEA is most accurate in
predicting the numbers of BRCA1/2 mutation carriers
combined compared with the other models with an AUC of
0.8 in females. It also had the closest predicted carrier
probability for both male and female cohorts. Both BO-
ADICEA and BRCAPRO models predicted the BRCA1
mutation carriage more accurately compared with the
BRCA2 mutation carriage, although BRCA1 mutation
carriage was better predicted by BRCAPRO: AUC was
0.87 (BOADICEA) and 0.93 (BRCAPRO), respectively.
Table 4 Observed and expected number of mutation by predicted carrier probability under BRCAPRO: females and males
Carrier prob (%) Observed Expected p value

No. AC prob No mutation BRCA1 BRCA2 No mutation BRCA1 BRCA2
n % n row% n row% n row% nn n
Female
\5 169 1.6 161 95.3 1 0.6 7 4.1 166.3 0.3 2.4 0.259
5t o\10 38 7.1 36 94.7 0 0 2 5.3 35.3 0.0 2.7 0.743
10 to\20 21 14.2 15 71.4 2 9.5 4 19 18 1 2 0.549
20 to\40 17 28.5 15 88.2 1 5.9 1 5.9 12.2 2.4 2.4 0.511
C40 40 70.9 20 50 11 27.5 9 22.5 11.6 15.6 12.8 0.162
Total 285 14.6 247 86.7 15 5.3 23 8.1 243.4 16.4 25.2 0.91
Male
\5 7 2.3 7 100 0 0 0 0 6.8 0 0.2 0.475
5t o\10 9 6.9 7 77.8 0 0 2 22.2 8.4 0 0.6 1.000
10 to\20 6 13.6 5 83.3 0 0 1 16.7 5.2 0 0.8 1.000
20 to\40 2 29.6 1 50 0 0 1 50 1.4 0 0.6 1.000
C40 1 97.2 0 0 0 0 1 100 0 0 1 1.000
Total 25 12.7 20 80 0 0 5 20 21.8 0 3.2 0.702
Carrier Prob (%) range of carrier probability for each proband data; No. number of probands in the corresponding range; AC Prob (%) average
carrier probability in the corresponding range
 Pearson v
2 goodness of ﬁt test
Table 3 continued
Mean Median Range tp value 95% CI
BRCA positive 33.03 16.3 9.02–96.51
All 12.33 8.64 0.04–96.51
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123Overall for the BRCAPRO and BOADICEA models, the
AUC of 0.8 for BRCA1/2 mutations combined were higher
than previous reports by Rao et al. (0.725) [34], Euhus
et al. (0.712) [47], Marroni et al. (0.757) [48], Antoniou
et al. (0.76) [49], and Kurian et al. (0.71 for Asians, 0.77
for whites) [33]. Possible reasons for predictions being
Table 5 Observed and expected number of mutation by predicted carrier probability under Myriad II: females and males
Carrier prob (%) Observed Expected p value

No. AC Prob No mutation Any BRCA No mutation Any BRCA
n % n row% n row% nN
Female
\5 46 2.9 45 97.8 1 2.2 44.7 1.3 1.000
5t o\10 161 6.7 148 91.9 13 8.1 150.2 10.8 0.671
10 to\20 45 15.8 35 77.8 10 22.2 37.9 7.1 0.419
20 to\40 27 33.8 16 59.3 11 40.7 17.9 9.1 0.573
C40 6 58.4 3 50.0 3 50.0 2.5 3.5 1.000
Total 285 11.2 247 86.7 38 13.3 253.1 31.9 0.444
Male
\5 1 2.8 1 100 0 0 0.97 0.03 1.000
5t o\10 0 0.0 0 0 0 0 0 0 –
10 to\20 21 12.8 18 85.7 3 14.3 18.3 2.7 1.000
20 to\40 2 21.8 1 50 1 50 1.6 0.4 1.000
C40 1 41.9 0 0 1 100 0.6 0.4 1.000
Total 25 14.3 20 80 5 20 21.4 3.6 1.000
Carrier Prob (%) range of carrier probability for each proband data; No. number of probands in the corresponding range; AC Prob (%) average
carrier probability in the corresponding range
 Pearson v
2 goodness of ﬁt test
Table 6 Observed and expected number of mutation by predicted carrier probability under BOADICEA: females and males
Carrier prob (%) Observed Expected p value

No. AC Prob No mutation BRCA1 BRCA2 No mutation BRCA1 BRCA2
n % n row% n row% n row% nn n
Female
\5 171 2.1 163 95.3 2 1.2 6 3.5 167.4 0.9 2.7 0.424
5t o\10 35 6.9 31 88.6 1 2.9 3 8.6 32.6 0.6 1.8 0.809
10 to\20 42 14.0 32 76.2 4 9.5 6 14.3 36.1 2.4 3.5 0.53
20 to\40 14 27.3 9 64.3 2 14.3 3 21.4 10.2 1.5 2.3 0.898
C40 23 69.9 12 52.2 6 26.1 5 21.7 6.9 8.8 7.3 0.326
Total 285 11.1 247 86.7 15 5.3 23 8.1 253.4 12.5 19.2 0.723
Male
\5 6 1.2 6 100.0 0 0.0 0 0.0 5.9 0.0 0.1 1.000
5t o\10 11 7.9 9 81.8 0 0.0 2 18.2 10.1 0.0 0.9 1.000
10 to\20 6 13.9 5 83.3 0 0.0 1 16.7 5.2 0.0 0.8 1.000
20 to\40 1 34.2 0 0.0 0 0.0 1 100.0 0.7 0.0 0.3 1.000
C40 1 96.5 0 0.0 0 0.0 1 100.0 0.04 0.0 0.97 1.000
Total 25 12.3 20 80.0 0 0.0 5 20.0 21.9 0.0 3.1 0.702
Carrier Prob (%) range of carrier probability for each proband data; No. number of probands in the corresponding range; AC Prob (%) average
carrier probability in the corresponding range
 Pearson v
2 goodness of ﬁt test
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123higher in our study may be attributed to the differences in
the prevalence of mutations, differences in mutation
spectrum, and penetrance. Most other studies performed in
Asians comprised a mixture of different Asian ethnic
groups, including Vietnamese, Koreans, Filipinos, Malays,
and Indians, whereas ours study was limited to southern
Chinese. Moreover, a prediction model’s accuracy is
dependent of the proband’s own account of family cancer
a b
c d
e
Fig. 1 a ROC curves among difference models in female comparing
BRCA carriers and noncarriers. Best model: BOADICEA,
ROC = 0.8, p\0.001. b ROC curves among difference models in
male comparing BRCA carriers and noncarriers. Best model:
BOADICEA, ROC = 0.87, p = 0.013. c ROC curves among differ-
ence models in female comparing BRCA1 and non-BRCA1 carriers.
Best model: BRCAPRO, ROC = 0.93, p\0.001. d ROC curves
among difference models in female comparing BRCA2 and non-
BRCA2 carriers. Best model: BOADICEA, ROC = 0.73, p\0.001.
e ROC curves among difference models in male comparing BRCA2
and non-BRCA2 carriers. Best model: BOADICEA, ROC = 0.87,
p = 0.013
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123history [50]. The reporting of family history may have
differed in other studies where three generations of family
history may not have been elicited which may also explain
the differences in the estimation of BRCA mutations using
these prediction models between studies [51]. Another
possible explanation for the differences is the use of gen-
der-speciﬁc analysis in our study. For the few males we
included in our study, we found that the models did not
have any different predictive probability between BRCA2
mutation carriers and noncarriers and they all underpre-
dicted BRCA2 mutations by nearly twofold (there were no
BRCA1 carriers). Risk prediction models should be used
with caution in males because there is a lack of studies to
assess the accuracy of the use of such models in male
cohorts alone. One Caucasian study did ﬁnd that BODI-
CEA 5.0 can achieve a prediction sensitivity of 0.8 for
BRCA1/2 and 0.63 for BRCA2 at 10% threshold [52]. A
larger cohort of male probands is necessary to allow further
conﬁrmation of our studies’ ﬁndings. Consistent with pre-
vious reported studies, we found that both BOADCIEA and
BRCAPRO models underestimated the number of muta-
tions carriers at a lower threshold and overestimated at a
higher threshold [53].
Recent studies have found that accuracy of risk pre-
diction models can be improved by incorporating patho-
logic information into the algorithm [54]. Moreover, the
use of risk-reduction strategies can affect the apparent
penetrance of mutations and affect the prediction accuracy.
Our previous studies found that approximately 20–30% of
women with BRCA mutation elected for prophylactic
contralateral mastectomy and salpingo-oophorectomy [55],
including unaffected family members of probands who
have found themselves to be mutation carriers. Revised
versions of the BRCAPRO model incorporate such infor-
mation [56] and may improve on the prediction accuracy
that we report here.
The strength of this study is its representation of the
broader Hong Kong population, because most cancer
genetics referrals are seen at our institution through the
referral to the Hong Kong Hereditary and High-Risk Breast
Cancer Programme. Unlike many prior studies, complete
genetictesting,includingfullgenesequencingandmultiplex
ligation-dependent probe ampliﬁcations (MLPA), was per-
formed on all patients to minimize the chance of false neg-
atives. Limitations include a clinic-based cohort rather than
population-based setting, and a relatively small sample size
especially for males, given the rarity of their disease.
We found underestimation of BRCA2 mutations in this
Chinese cohort by standard mutation prediction models,
despite relatively satisfactory discriminative ability; given
that BRCA2 mutations are more prevalent in Asian and
male cohorts, this ﬁnding has clinical signiﬁcance. Further
studies in larger cohorts, including Asians and males, are
indicated, with the goal of developing an accurate predic-
tive model speciﬁc to these populations and of targeting
genetic testing more accurately for optimal patient care.
Table 7 Performance of BRCAPRO, Myriad II, Couch and Shattuck-Eidens, and BOADICEA at conventional thresholds of 10% and 20%
Conventional
threshold (%)
Sensitivity at conventional threshold (%) Speciﬁcity at conventional threshold (%)
BRCA carrier vs.
non-carrier
BRCA1 vs.
non-BRCA1
BRCA2 vs.
non-BRCA2
BRCA carrier vs.
non-carrier
BRCA1 vs.
non-BRCA1
BRCA2 vs.
non-BRCA2
Female model
BRCAPRO 10 73.7 86.7 43.5 79.8 86.7 90.1
20 57.9 66.7 34.8 86.2 91.5 94.3
Myriad II 10 63.2 – – 78.1 – –
20 34.2 – – 92.3 – –
Couch 10 – 80 – – 64.8 –
20 – 46.7 – – 90.7 –
Shattuck-Eidens 10 – 66.7 – – 80.4 –
20 – 46.7 – – 93 –
BOADICEA 10 68.4 60 30.4 78.9 89.3 90.8
20 42.1 46.7 17.4 91.5 94.1 96.9
Male model
BRCAPRO 10 60 – 60.0 75 – 75
20 40 – 40.0 95 – 95
Myriad II 10 40 – – 95 – –
20 20 – – 100 – –
BOADICEA 10 60 – 60 80 – 85
20 40 – 40 100 – 100
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